| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 19,476 | 6,459 |
| Depreciation and amortization | 4,642 | 3,126 |
| Operating lease right-of-use assets expense | 6,400 | 4,301 |
| Foreign currency remeasurement loss | -4,302 | -4,053 |
| Stock-based compensation | 31,441 | 20,763 |
| Deferred income taxes | -3,617 | -155 |
| Allowance for credit loss on notes receivables | 4,037 | - |
| Other | -78 | -1,091 |
| Change in value of earn-out and warrant liabilities | 408 | 408 |
| Accounts receivable | -2,210 | -285 |
| Prepaid expenses and other current assets | 972 | -2,591 |
| Deferred contract costs and other assets | 8,616 | 5,438 |
| Accounts payable, accrued expenses, other current liabilities, operating lease liabilities and other liabilities | -16,167 | -23,872 |
| Deferred revenue | 12,792 | 7,969 |
| Net cash provided by operating activities | 55,598 | 20,765 |
| Maturities of investments | 140 | 0 |
| Purchases of investments | 140 | 0 |
| Repurchase of noncontrolling interest | 12,148 | 12,148 |
| Capitalization of internal-use software | 1,162 | 812 |
| Purchase of property and equipment | 2,986 | 2,479 |
| Issuance of notes receivables | 0 | 0 |
| Cash paid in business combinations, net of cash acquired | 14,893 | 14,893 |
| Other investing activities | 0 | - |
| Net cash used in investing activities | -31,189 | -30,332 |
| Purchase of common stock | 27,309 | 18,954 |
| Proceeds from warrant exercises | 168,189 | 157,723 |
| Proceeds from stock option exercises | 8,519 | 8,029 |
| Funds held on behalf of others | 6,064 | - |
| Redemption of redeemable noncontrolling interest | 0 | - |
| Purchase of public warrants | 0 | - |
| Repayments of finance leases | 5 | 4 |
| Redemption of warrants | 2 | - |
| Net cash provided by (used in) financing activities | 155,456 | 146,794 |
| Effect of exchange rates on cash | 1,040 | 1,854 |
| Net increase in cash and cash equivalents | 180,905 | 139,081 |
| Cash and cash equivalents at beginning of period | 290,735 | - |
| Cash and cash equivalents at end of period | 471,640 | - |
AvePoint, Inc. (AVPT)
AvePoint, Inc. (AVPT)